General Information
| Short Description | RUNX2 Blocking Peptide for STJ502837 is synthetically produced from the 10-50 sequence and is suitable for use in western blot applications. |
| Applications | Immunodepletion/Immunocompetition |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Formulation | Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice. |
| Storage Instruction | Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
Target Information
| Immunogen | Synthetic peptide taken within amino acid region 10-50 on human RUNX2 protein. |
| Immunogen Region | 10-50 |
| Specificity | This blocking peptide is recommended for use in combination with RUNX2 antibody, STJ502837 |
Additional Info
| Background | Transcription factor involved in osteoblastic differentiation and skeletal morphogenesis. Essential for the maturation of osteoblasts and both intramembranous and endochondral ossification. CBF binds to the core site, 5 NA-PYGPYGGT-3 NA, of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, osteocalcin, osteopontin, bone sialoprotein, alpha 1 (I) collagen, LCK, IL-3 and GM-CSF promoters. In osteoblasts, supports transcription activation: synergizes with SPEN/MINT to enhance FGFR2-mediated activation of the osteocalcin FGF-responsive element (OCFRE) (By similarity). Inhibits KAT6B-dependent transcriptional activation. |
Information sourced from Uniprot.org